Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half of 2025. These steps are key as the company focuses on evaluating whether Berubicin has potential to address GBM, the most aggressive type of brain cancer, which has an average survival of only 14 to 16 months after diagnosis and no cure. “There remains a tremendous unmet medical need for an effective treatment for GBM, and we are dedicated to advancing this important program forward to bring much needed hope for patients,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Over the course of 2023, we made significant progress with our lead development program, Berubicin, having recently achieved four primary objectives toward which we were actively working: maintain a rapid pace of enrollment to reach our preplanned interim analysis; complete planned enrollment; bolster buy-in from investigators; and expand our board indicating a strong support system from industry leaders. In addition to reaching complete enrollment, we have also successfully completed the interim futility analysis and received a recommendation from the independent Data Safety Monitoring Board to continue the study without modification, which we believe is a monumental step towards our objective of seeing Berubicin approved.”

To view the full press release, visit

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in CNS Pharmaceuticals Inc. CNSP. Bookmark the permalink.

Comments are closed.